. Impact of time since diagnosis and mortality rate on cancer-associated venous thromboembolism:
Summary. Background: Venous thromboembolism (VTE) is a common complication in cancer, and studies have suggested that aggressive cancers create the highest risk of VTE. However, competing risk by death may result in overestimation of VTE risk in patients with cancers associated with high mortality. Therefore, we estimated the risk of VTE by cancer site, accounting for the differential mortality between cancers. Methods: The Scandinavian Thrombosis and Cancer cohort included 144 952 participants followed from 1993-1997 to [2008] [2009] [2010] [2011] [2012] . Incidence rates, cause-specific hazard ratios (HRs) and subdistribution HRs (SHRs) were assessed for overall cancer and by cancer site according to time intervals since cancer diagnosis. Results: During follow-up, 14 272 subjects developed cancer, and 567 had cancer-related VTE. In cause-specific analyses, the VTE risk was highest in the first 6 months after cancer diagnosis (HR 17.5, 95% confidence interval [CI] 15.1-20.3), and declined rapidly thereafter. However, when mortality was taken into account, the risk was similar in the periods 6 months before (SHR 4.8, 95% CI 3.6-6.4) and 6 months after (SHR 4.6, 95% CI 3.9-5.4) cancer diagnosis. The range of the 2-year cumulative VTE incidence rates was substantially narrowed for all cancer sites after competing risk by death was taken into account (from 1-10% to 1-4%). Conclusion: VTE risk by cancer site was influenced by the mortality rate and the time since cancer diagnosis. Our findings suggest that the cancer itself is a major contributor to VTE risk, and that competing risk by death should be taken into account when VTE risk in cancer is explored.
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Introduction
Deep vein thrombosis (DVT) and pulmonary embolism (PE), together referred to as venous thromboembolism (VTE), are common complications in patients with cancer. Previous studies have indicated that ⁓ 20% of all first life-time VTE events can be attributed to cancer [1] , and that cancer patients have a four-fold to seven-fold higher risk of VTE than cancer-free subjects [2] [3] [4] . However, because of a concomitant increased risk of bleeding in cancer patients, prophylactic anticoagulation is not recommended for these patients on a general basis [5] . Therefore, identification of high-risk subjects with a favorable benefit-to-harm ratio for thromboprophylaxis is crucial.
Several studies have reported incidence rates of VTE according to specific cancer sites [6] . However, variations in study populations, study designs, duration of follow-up and outcome registration make it difficult to compare rates derived from individual studies. Moreover, the rate of VTE may vary according to the time since cancer was diagnosed [2] . Several registry-based studies [2, 3, [7] [8] [9] and a meta-analysis [6] have suggested that cancers of the pancreas, lungs and brain are associated with the highest VTE risk, whereas breast, prostate and colorectal cancers are associated with a substantially lower VTE risk. However, the cancer sites with high VTE risk are also associated with high mortality rate [1] , and it has been emphasized that VTE risk in patients with cancer sites associated with high mortality is probably overestimated, as death is a competing event [10, 11] . Few studies have compared VTE risk according to different sites while accounting for time since cancer diagnosis and competing risk by death. Thus, it is not known whether the reported high-risk estimates of VTE shown for aggressive cancers result from true cancer-specific thrombogenicity, or merely reflect a situation with high mortality and limited follow-up for certain cancer sites.
In this study, we aimed to assess the overall and timespecific VTE risk in cancer patients recruited from three large population-based cohorts. Moreover, we aimed to compare the short-term cumulative incidence for each cancer site, taking competing risk by death into account.
Materials and methods

Study population
The Scandinavian Thrombosis and Cancer (STAC) cohort is a merging of three population-based cohorts in Scandinavia: the fourth survey of the Tromsø Study (Tromsø IV, Norway), the second survey of the NordTrøndelag health study (HUNT2, Norway) and the Diet, Cancer and Health (DCH) Study (Denmark). Both the individual cohorts [12] [13] [14] and the STAC cohort [15] have been described in detail elsewhere. In Tromsø IV, all inhabitants aged ≥ 25 years living in the municipality of Tromsø were invited, and 27 158 subjects (77%) participated. Enrollment of participants took place in 1994-1995. In HUNT2, subjects aged > 19 years living in the county of Nord-Trøndelag in the period 1995-1997 were invited, and 65 237 subjects (69%) participated. In the DCH Study, subjects aged 50-64 years living in urban areas of Copenhagen and Aarhus without a history of cancer were invited. Recruitment took place between 1993 and 1997, and 57 053 subjects (35%) participated. The studies were approved by the regional ethical committees in Tromsø and Trøndelag (Norway), and Copenhagen and Aarhus (Denmark), and subjects gave their informed written consent to participate. Participants with a prebaseline diagnosis of cancer or VTE were excluded from all cohorts before the merging, yielding a study population of 144 952 subjects.
Baseline information
Baseline information was obtained by physical examination and with self-administered questionnaires. Blood pressure and anthropometric measures were recorded by trained personnel using standardized methods, as described elsewhere [13, 16, 17] . Hypertension was defined as systolic blood pressure of ≥ 140 mmHg, diastolic blood pressure of ≥ 90 mmHg, self-reported hypertension, or current use of antihypertensive medications. Body mass index was calculated as the weight in kilograms divided by the square of the height in meters. Information about lifestyle factors, including smoking habits, physical activity level, and alcohol consumption, was collected by use of the self-administered questionnaires. Uniform questions about smoking across the studies were current smoking (yes/no) and number of daily cigarettes. Alcohol consumption was defined as the reported average number of units per week. Subjects also answered questions about hypertension, diabetes, and current medications, including blood pressure-lowering drugs.
Cancer assessment
Cancer registration is mandatory by law in both Norway and Denmark. Individual data from the three cohorts were linked to the Norwegian and Danish cancer registries by use of the unique national civil registration number, which is assigned to every Norwegian and Danish citizen at birth. The obtained information included date of cancer diagnosis, location of the disease (ICD10 codes C00-96), histological grade (ICO-3), and cancer stage (localized, regional, distant, or unknown). Subjects with non-melanoma skin cancers (ICD10 C44) were regarded as being cancer-free. Both cancer registries are considered to be complete and valid, and evaluations have reported 98.8% completeness in Norway and 95-98% completeness in Denmark, with 94% and 93% microscopically confirmed diagnoses, respectively [18, 19] .
VTE assessment
All symptomatic, objectively confirmed, first lifetime VTE events that occurred among the participants during follow-up were recorded. Potential cases of VTE were identified by searching relevant discharge diagnosis registries, radiology procedure registries, cause of death registries and autopsy registries at all hospitals covering each study site, as previously described in detail [15] . The medical records of each potential VTE case were thoroughly reviewed, and validated according to essentially similar confirmatory criteria in each cohort [13, 14, 16] . A VTE event was included when typical signs and symptoms of DVT or PE were described in the medical record and objective diagnostic tests confirmed the diagnosis (e.g. compression ultrasonography, venography, spiral computed tomography, perfusion-ventilation scan, pulmonary angiography, echocardiography, and autopsy). Events identified through the autopsy registry were included if VTE was noted as the cause of death or as a significant condition contributing to death on the death certificate. In the DCH Study, these events were identified through the National Death Registry, and were included only if VTE was confirmed by autopsy.
Study design
Person-years were calculated from the date of inclusion in 1993-1997 until the date of VTE, migration, death or end of follow-up for the respective cohorts, whichever came first. End of follow-up dates for VTE were as follows: 31 December 2007 in HUNT2; 30 April 2008 in the DCH Study; and 31 December 2012 in Tromsø IV. Cancer was treated as a time-dependent exposure variable, whereby the period from inclusion until 1 year prior to cancer diagnosis was considered to be cancer-free time, followed by 1 year of occult cancer exposure, whereas overt cancer exposure was calculated from the date of cancer diagnosis and onwards. Thus, subjects who developed cancer during follow-up contributed with three distinct observation periods. Those with a cancer diagnosis within the first year after migration from the municipality or end of follow-up date (n = 1 591) contributed with occult cancer exposure until the date of migration or end of study. Because of the potential delay in cancer registration, participants who were diagnosed with VTE within the last 30 days before cancer were excluded from the analyses of VTE risk in time intervals.
Statistical analyses
Statistical analyses were conducted with STATA version 14 (Stata Corporation, College Station, TX, USA). Overall and cancer site-specific incidence rates of VTE for every 6-month interval starting 1 year before the cancer diagnosis and up to 2 years after were calculated and expressed as number of events per 1000 person-years.
Cox proportional hazards regression models with cancer as a time-varying covariate were used to calculate cause-specific hazard ratios (HRs) with 95% confidence intervals (CIs) of VTE according to cancer site compared with cancer-free exposure time. Age was used as the timescale in the Cox regression models, sex was entered as a covariate, and the stsplit command was used to evaluate the risk across time intervals before and after cancer diagnosis. The relative VTE risk according to each specific time interval was assessed with the overall risk in cancerfree exposure time during the entire study period as the reference. The time intervals were: 12-6 months before, 6-0 months before, 0-6 months after, 6-12 months after, 12-18 months after, 18-24 months after and > 24 months after cancer diagnosis. Subdistribution HRs (SHRs) taking competing risk by death into account were assessed with the stcrreg command in STATA. Differences in risk estimates between studies may rely on the length of follow-up. Thus, to evaluate the effect of extending follow-up time after cancer diagnosis on the risk estimates of VTE, we calculated HRs and SHRs in increasing time intervals following cancer diagnosis (0-3 months, 0-6 months, 0-1 year, 0-2 years, 0-3 years, 0-4 years, 0-5 years, and entire follow-up period).
The cumulative incidence of VTE is often overestimated when the mortality rate is high [10] . Therefore, the 2-year cumulative incidence of VTE within each cancer site was estimated in regular cumulative hazards analyses and in analyses taking competing risk of death into account by use of the cumulative incidence function based on the Fine and Gray model [20] .
Results
The mean age at inclusion was 52 years, and 47% of the participants were men. Baseline characteristics are shown in Table 1 . During follow-up, 14 272 subjects developed cancer, and cancer and non-cancer subjects were followed for median periods of 2.3 years and 11.6 years, respectively (Table 2) . Prostate, breast, colorectal and lung cancers were the most frequent cancers in the population, and each of these cancer types accounted for 11-17% of the cancer diagnoses.
A total of 2444 VTE events occurred during the study period. VTE events that occurred in the year before cancer (n = 113) or after manifest cancer diagnosis (n = 454) were considered to be cancer-related (n = 567), whereas the remaining 1877 events that were registered in subjects without cancer or > 1 year before cancer diagnosis were categorized as non-cancer VTEs ( Table 2 ). The proportions of VTE events that presented as PE (with or without concurrent DVT) were similar for cancer-related and non-cancer VTEs, being 39% and 41%, respectively (Table 2 ). In total, 66 of the VTE patients died on the same day as the VTE was diagnosed. The HRs and SHRs of VTE in 6-month intervals from the year before cancer and up to 2 years after cancer diagnosis are shown in Fig. 1 . In the cause-specific analyses, the HR of VTE began to increase substantially in the last 6 months before cancer diagnosis, and patients with occult cancer had a four-fold higher risk of VTE than cancer-free subjects (HR 4.1; 95% CI 3.0-5.5) in this period (Fig. 1) . In the initial 6 months after cancer diagnosis, the risk of VTE was almost 18-fold higher than in the reference population (HR 17.5, 95% CI 15.1-20.3). Thereafter, the risk estimates dropped substantially over time, but the risk was still 2.5-fold (HR 2.5, 95% CI 2.1-2.9) higher than in non-cancer subjects in the period > 24 months after cancer diagnosis. However, when competing risk by death was taken into account, the risk estimates dropped dramatically, and were essentially similar in the periods 6 months before (SHR 4.8, 95% CI 3.6-6.4) and 6 months after (SHR 4.6, 95% CI 3.9-5.4) cancer diagnosis. Furthermore, the SHRs were lower than the cause-specific HRs in all time intervals after cancer diagnosis (Fig. 1) .
The incidence rates of VTE were highest within the first 6 months after cancer diagnosis for almost all sites, and, among the sites, pancreatic, stomach, lung and renal cancer showed the highest incidence rates (Table 3) . However, the rates were probably overestimated in these sites, owing to the concomitant high mortality rates. Figure 2 shows the 2-year cumulative incidence of VTE based on the regular approach (left panel) and after taking competing risk into account (right panel). With the standard approach, the cumulative incidence of VTE 2 years after cancer diagnosis ranged from 10% for pancreatic cancer to ⁓ 1% for breast and prostate cancer. However, when competing risk of death was taken into account, the cumulative incidence rates were narrowed, and ranged between 1% and 4% for all sites, with pancreas, lung and kidney cancer showing similar incidence rates (⁓ 3.5%).
The effect of extending follow-up after cancer diagnosis on the VTE risk estimates is shown in Table 4 . The HR declined substantially from 20.7-fold when the study period was restricted to the first 3 months, to 8.7-fold when it was prolonged to 2 years, to 6.0-fold when it was prolonged to 4 years, and to 4.9-fold when the entire followup period (> 10 years) was applied. Almost all cancer sites followed this general pattern of decreasing risk estimates over an extended follow-up time. In the competing risk analyses, the risk estimates were substantially lower than the standard HRs in all time intervals, but followed the same pattern of estimates declining over an extended follow-up time.
Discussion
The main purpose of the study was to investigate VTE risk according to time intervals since cancer diagnosis and by cancer site, accounting for differential mortality between cancers. VTE risk was apparently highest in the 6 months after cancer diagnosis, and declined rapidly thereafter. When mortality was taken into account, the *Information on VTE localization was missing for 34 subjects, so DVT + PE does not sum up to the total number of VTEs. †One thousand five hundred and ninety-one subjects developed cancer in the first year after the study period and participated with < 1 year of occult cancer exposure. ‡The numbers are population-based proportions, not sex-specific.
risk estimates were substantially lowered, and became equally high in the periods 6 months before and 6 months after cancer diagnosis. The general pattern was that the high cause-specific HRs of VTE in cancers with a high mortality rate were substantially attenuated when competing risk by death was taken into account. All risk estimates declined, in both the conventional and the competing risk approaches, over increasing follow-up time since cancer diagnosis. Our findings challenge established concepts in the epidemiology of cancer-related VTE: first, whether cancer sites that are apparently associated with high thrombosis risk, such as pancreatic, lung and brain cancers, actually are sites with high VTE risk, or merely represent proxies for high mortality; and second, whether the apparently high initial VTE risk after cancer diagnosis, reported in the present and previous publications, is precipitated by treatment-related factors (e.g. surgery, chemotherapy, and radiotherapy) and complications (e.g. immobilization and infections), or is actually an overestimation of risk resulting from a corresponding high mortality in this period. Over the past decade, there has been an increased focus on the presence of competing risk by death in cancer and thrombosis studies. In regular Kaplan-Meier (KM) and Cox regression analyses, death is managed by censoring. Censoring assumes that the probability of the study outcome remains unaltered thereafter. However, when death occurs, the probability of a subsequent thrombosis instantly drops to zero. Therefore, it has been argued that death should be managed as a competing event rather than by censoring in studies with substantial mortality, particularly if the study purpose is to develop risk prediction models or risk score systems [21] . Ay et al. compared the performance of the standard KM estimator, the log-rank test, and the Cox regression model with specific competing risk methods in a cancer cohort [10] . They demonstrated that standard methods generally overestimated the risk of VTE, and, for the 1 -KM estimator, the degree of bias was proportional to the degree of competing mortality [10] . The authors concluded that bias could be considerable in cancer populations with high mortality. Similarly, Campigotto et al. [11, 22] found that the 1 -KM estimator overestimated VTE risk by up to 280% as compared with the competing risk analyses in simulated cohorts with 5-month, 2-month and < 1-month survival.
In agreement with Campigotto et al. [11] , the overall 0-6-month cause-specific HR of VTE was overestimated by 380% in our real-life cohort study, as compared with the competing risk analysis (HR 17.5 versus SHR 4.6). Previous studies have reported a high risk of VTE in the initial period after a cancer diagnosis [2] [3] [4] , and this was linked to the accumulation of iatrogenic risk factors and comorbidities in this period [1] . However, these studies did not take competing risk by death into account. The substantial drop in the risk estimate in the competing risk analysis in our study suggests that the previously reported high VTE risk shortly after cancer diagnosis reflects, to a large extent, the high mortality rate in this period, and that the absolute VTE risk may be substantially lower than anticipated. In addition, our findings showed that VTE risk was almost the same in the periods 6 months before and 6 months after cancer diagnosis in the competing risk analyses. As it is reasonable to assume that Age-adjusted and sex-adjusted cause-specific hazard ratios (HRs) of venous thromboembolism (VTE) and subdistribution HRs (SHRs) taking competing risk by death into account according to time intervals before and after cancer diagnosis. The 30-day period before the cancer date was excluded because of unknown temporality between cancer and VTE (i.e. potential delay in cancer registration).
subjects were unexposed to treatment-related factors (e.g. chemotherapy and intravascular catheters) and complications (e.g. immobilization and infections) in the prediagnosis period, these risk estimates indicate that the cancer itself is a major contributor to VTE risk in cancer patients. Previous studies have reported VTE risk according to cancer site, treating death from causes other than VTE as a censoring event. In a Danish registry-based study, multiple myeloma, brain and pancreatic cancers had the highest risk estimates, with HRs ranging from 46 to 16 for these cancers [2] . Likewise, Walker et al. [3] reported the highest rates for pancreatic cancer, followed by mesothelioma, unknown primary site, lung cancer, and brain cancer. In a systematic review by Horsted et al. [6] , VTE risk was highest among patients with pancreatic, brain and lung cancers. Accordingly, in our study, the cause-specific HRs were highest for pancreatic, lung and brain cancers, and substantially lower for cancers such as breast and prostate cancers. However, the competing risk analyses showed that both the HRs and the cumulative incidence rates were substantially overestimated in the high-risk sites, owing to concomitant high mortality. In fact, the 2-year cumulative incidence rates were narrowed and varied within the range of 1-4% for all sites when death was taken into account. These figures are important, and clearly demonstrate that awareness of thrombosis risk in cancer patients should be emphasized in a wider range of cancer subtypes, than those included for instance in the Khorana-model [23] . Our findings also support the suggestion of Ay et al., who emphasize that studies with imbalanced mortality rates between study arms, as well as prognostic studies with potential impact on clinical decision-making, should be reanalyzed with the competing risk approach [10] .
In the present study, we showed that the risk estimates of VTE in cancer patients were dependent on the followup time of the study, even when death was accounted for as a competing event. As expected, the largest effect of extending follow-up time was seen in the conventional approach, where the risk estimates dropped from 21-fold for the period 0-3 months to six-fold for the period 0-5 years. In the competing risk analyses, all SHRs were substantially lower than the HRs, but the risk estimates still dropped from 4.5-fold for the period 0-3 months to 2.7-fold for the period 0-5 years. During extended follow-up, subjects who survive their cancer could go into remission. This would result in exposure misclassification, which could potentially dilute the association between exposure and outcome during extended follow-up.
The main strength of this study is the large sample size, which has enabled analyses of validated VTE data across all the common subtypes of cancer in a prospective cohort. The completeness and validity of the cancer registries in Norway and Denmark are very high [18, 19] , and Incidence rates (IR) with 95% confidence intervals (CI) in parenthesis.
the broad age-span of the participants meant that they formed a representative cohort corresponding to nationwide cancer statistics in the Nordic countries [24, 25] . Unfortunately, information about cancer treatment was not available in our study and could not be used in the analyses. Moreover, the treatment and management of cancer have rapidly evolved over the years, resulting in an increased mean survival time for some cancer types. In the DCH Study and HUNT2, the follow-up ended in 2007-2008, and our results may therefore not be fully representative of the situation today. The VTE identification procedure was performed according to slightly different criteria in the three cohorts, and the incidence rate of VTE showed some variation in the three cohorts [15] . In the cancer and thrombosis setting, a differential distribution of undiagnosed VTE events may be present. However, it can be argued that VTE rates in cancer populations are prone to both higher and lower relative diagnosis rates than those in non-cancer patients, because of either: (i) a higher clinical suspicion because of known cancer; or (ii) clinical decisions to refrain from diagnostic examinations, because of poor prognosis and/or comorbidities. Fatal PE, however, is probably more common in cancer patients, and often remains undiagnosed. As the autopsy rates in cancer patients are low, missed diagnoses of fatal VTEs in cancer patients may have resulted in an overestimation of the competing risk of death by cancer, and the true competing risk estimates probably lie somewhere between the reported HRs and SHRs.
In conclusion, the present study showed that the risk of VTE changed significantly according to the time since cancer diagnosis in cause-specific analyses, and that the risk estimates dropped substantially, particularly in the initial period, when competing risk by death was taken into account, owing to the concomitant high mortality rate. Our findings suggest that the cancer itself rather than treatment-related factors is the main contributor to VTE risk in cancer patients, and that competing risk by death should be taken into account, in addition to cancer site, when VTE risk in cancer patients is predicted. 
